Related Experiment Videos
Dose-response relationship to dacarbazine demonstrated in a patient with malignant melanoma
Abstract:
Dacarbazine has shown the most consistent activity of any single chemotherapeutic agent in patients with metastatic melanoma. While the overall rate is 21%, responses fall to less than 10% when hepatic metastases are present. We report a patient with malignant melanoma metastatic to the liver in whom an apparent dose-response relationship to dacarbazine was demonstrated. His liver metastases responded to hepatic artery infusion, progressed with systemic iv therapy, and responded upon reinstitution of hepatic artery infusion.
Insights
Dacarbazine shows consistent activity in metastatic melanoma. However, this case suggests hepatic artery infusion may improve response rates in patients with liver metastases.
Area of Science:
- Oncology
- Medical Oncology
- Cancer Research
Background:
- Metastatic melanoma is a significant clinical challenge.
- Dacarbazine is a primary chemotherapeutic agent for metastatic melanoma.
- Hepatic metastases negatively impact treatment response rates.
Observation:
- A patient with malignant melanoma metastatic to the liver was treated.
- The patient received dacarbazine via systemic intravenous therapy and hepatic artery infusion.
- Treatment responses were monitored in relation to the administration method.
Findings:
- A dose-response relationship to dacarbazine was observed in the patient.
- Liver metastases initially responded to hepatic artery infusion.
- Metastases progressed during systemic intravenous dacarbazine therapy.
- Reinstitution of hepatic artery infusion led to renewed response.
Implications:
- Hepatic artery infusion may be a viable strategy for managing liver metastases in melanoma.
- This case highlights a potential method to optimize dacarbazine efficacy.
- Further research into regional chemotherapy delivery for melanoma with liver involvement is warranted.